Evidence is presented for two different breast epitheial antigens that some epitopes have greater tumor specificity and are more effective targets for radioimmunotherapy than others. The two antigens, which are major components of the human milk fat globule membrane, are breast mucin and a Mr 46'000 glycoprotein (BA46 
Introduction
The ideal MAb3 for use as a targeting agent for therapy of breast cancer would be one that targeted a tumor-specific antigen. However, the identification of such truly breast tumor-specific antigens has been elusive. Our approach has been to develop MAbs against normal breast epithelial antigens and select epitopes that are preferentially expressed in breast carcinomas. The two antigens described here are both major components of the normal HMFG membrane, which is derived from the apical surface of the breast epithelial cell during lactation.
The first antigen is a highly glycosylated, large molecular weight glycoprotein referred to as breast epithelial mucin. The breast mucin is highly immunogenic (1) in that the majority of MAbs that have been prepared against breast carcinoma cells, their membranes, and HMFG membranes have been found to identify epitopes on this molecule (1, 2) . Nearly all MAbs that bind to the core peptide (encoded by the MUC-1 gene; Ref. 3) have epitopes on an internal tandem repeat domain of the breast mucin (4) . In spite of this, â€Presentedat the â€oeFifth Conference on Radioimmunodetectionand Radioimmuno therapy of Cancer.â€•October 6â€" 8. 1994 , Princeton, NJ. This work was supported in part by NIH Grants CA39936, CA39932, and CA42767. globule; EGF, epidermal growth factor; MXDTPA, 1-p-isothiocyantobenzyl-3-methyl diethylenetnaminepentaacetic acid; RGD. arginine-glycine-aspartic acid.
however, they differ considerably in their biodistribution in normal and tumor tissues (1) . The second antigen is a Mr 46,000 glycoprotein (BA46) that, through cDNA sequencing and cell binding assays, appears to be a cell membrane-associated adhesion molecule. We have developed numerous MAbs against these two HMFG antigens and present cvi dence here that for both antigens, different epitopes can differ in their effectiveness as targets for radioimmunotherapy. Purification of BA46 Adhesion Molecule. Fresh human milk was centri fuged at 2,000 x g for 5 mm at 4Â°C, and the cream fraction was removed, resuspended in PBS, and centrifuged again. The washed cream was resus pended in 2% Triton X-1l4 in PBS and incubated at 37Â°Cfor 1 h with occasional vortexing. It was then centrifuged at 10,000 X g for 20 mm at 4Â°C, the top fat layer was removed, and the supernatant was saved, discarding the pellet. The protein concentration was determined by the BCA method (Pierce, Rockford, IL). Cell Adhesion Assays. Adhesion assays of 3T3-L1E mouse fibroblasts were performed basically as described by others (9) . The HMFGs, suspended in PBS diluted 1:500 from its original concentration in milk and Triton X-114
(I mg/ml) diluted 1:1000, were added to untreated polystyrene, 96-well mi crotiter plates with flat-bottomed wells (Nunc, Naperville, IL) in duplicate (60 p3/well)and were allowed to bind overnight at 4Â°C. Control solutions PBS and 0.9% BSA were tested in parallel. On the next day, the solutions were removed, and the wells were blocked with DME containing 1% BSA at 37Â°C for approximately 45 mm. 3T3-L1E cells were cultured in DMEM (Sigma), 10% fetal bovine serum, and 1% penicillin/streptomycin solution. On the day before the assay, DME + 1% penicillin/streptomycin solution was added to the cells. The next day, 3T3-L1E cells were removed from the flasks with 0.02%
EDTA and suspended in DME + 1% BSA; then l0@cells in the presence of different concentrations of GRDGSP or GRGESP peptides were added to the wells and incubated at 37Â°C for 1 h. Unbound cells were removed by washing twice with PBS. Bound cells were then fixed with 1% acetic acid in methanol Determination of Antibody Affinity. The affinities of the MAbs for the native antigen and fusion proteins were determined by an antibody displace ment method described by Sheldon et a!. (12) . The antigen was bound to the solid phase of microtiter wells, and a constant amount of â€231-labeledMAt, was added with increasing amounts of unlabeled MAb. The molar concentration of Competition Assay with Anti-Mucin MAin. For testing for competition among different Anti-breast mucin MAbs for their epitopes, 96-well microtiter plates were coated with delipidated HMFG (100 ng/well) or a synthetic tandem repeat peptide (APPAHGVTSAPDTRPAPGST; 125 ng/well) as described previously (10) . MAbs Mc5 and BrE-3 were iodinated using the chloramine-T method, as described previously (11) . Approximately 2 X 106 cpm of @as1@ labeled Mc5 or BrE-3 were mixed with different concentrations of the unla beled MAbs in RIA buffer (PBS, 0.3% Triton X-lOO,and 10% calf semm), added to the coated wells, and incubated overnight at room temperature. The wells were then washed extensively with RIA buffer, and the radioactivity was determined in each well cut from the plate. glycosylated mucin from HMFG and a nonglycosylated synthetic tandem repeat peptide (Fig. 2) (Fig. 2) . In contrast, on a synthetic peptide of the tandem repeat, equivalent competition was seen for cold Mc5, Mc!, BrE-2, and BrE-3. BrE-l also competed but to a lesser degree. When BrE-3 was labeled, cold Md, Mc5, and BrE-l showed little competition for binding to HMFG. However, BrE-2 competed equally or better than cold BrE-3 itself. This latter competition result is consistent with the observation that both the latter MAbs recognize the amino acid sequence TRP on the tandem repeat ( Fig. 1) , although their tissue distributions are different (1) . When the competition was done using the synthetic peptide, cold
Mc5, Mc 1, BrE-2, and BrE-3 all competed equally well with labeled BrE-3, while BrE-l did not. The lack of competition with BrE-l, although the amino acid epitope overlaps with BrE-3, could be due to its lower affinity for the peptide. It is interesting to note that BrE-l is the most breast tumor specific of the five MAbs in that it shows no binding at all to normal breast (1). These competition results indicate that there is heterogeneous glycosylation of the tandem repeats in the native breast mucin, resulting in an array of unique and different epitopes identified by these MAbs. The distribution and prevalence of these epitopes appear to be different in breast tumor cells due to alterations in glycosylation, as described below. Since Mc5 was the most extensively studied preclinically and since it bound strongly to breast carcinomas, it was our first candidate for human clinical trials. One advantage of the tandem repeat domain as a target for MAb therapy is its polyepitopic nature, thus providing multiple targets on the surface of breast cancer cells. Also, because of the cell heterogeneity of expression of such epitopes on breast carci noma cells, radioconjugated MAbs are preferable, since every cell need not bind the MAb for achieving cytotoxicity for the localized tumor (1 1). As a prerequisite for radioimmunotherapy, clinical imag ing trials were initiated in which 12 breast cancer patients were injected with â€˜311-labeled Mc5 (16) . Disappointingly, in only one patient was there any significant imaging of metastatic disease (16) . In an effort to explain this lack of imaging, serum levels of the Mc5 epitope on circulating antigen were determined, and it was found that all patients had detectable levels in their serum. In contrast, in the same serum samples from these patients, the level of the BrE-3 epitope was 5â€"10-foldlower (4) . Therefore, differences between the epitopes of Mc5 and BrE-3 were explored further. Epitope mapping of the polypeptide epitopes of Mc5 and BrE-3 on the tandem repeat region of the breast mucin revealed that they have overlapping linear amino acid sequences of DTRPAP and TRP, respectively, in their epitopes ( Fig. 1; Ref. 17) . In spite of this, the binding affinity of Mc5 was significantly affected by the degree of glycosylation of the breast mucin in that the affinity on the fully glycosylated, mature breast mucin isolated from HMFG was significantly higher (disassociation constant, 3.63 X l0@) than on the deglycosylated mucin (hydrogen fluoride method; 1.62 X 10_a) or on the nonglycosylated core protein produced in bacteria as a fusion protein (1.0 X l0â€"@) (4, 7) . This indicated that oligosaccharide structures on the mature mucin are either part of the Mc5 epitope or glycosylation alters the polypeptide configuration to yield the highest affinity peptide epitope structure on the breast mucin. In contrast, the affinity constant for BrE-3 was not affected by the degree of glyco sylation of 1.66 X lO_8 for the mature mucin, 1.56 X lO_8 for the deglycosylated mucin, and 1.15 X lO_8 for the fusion protein. MAb McS bound strongly to both normal breast (apical staining only) and breast carcinomas (membrane and cytoplasmic staining), while BrE-3 bound strongly to breast carcinomas (membrane and cytoplasmic staining) but only weakly to normal breast epithelial cells (1). Because BrE-3 stained the majority of breast carcinomas immuno histochemically and its epitope was expressed at relatively low levels on circulating mucin compared to the Mc5 epitope, clinical trials with BrE-3 were initiated. In this case, the imaging trials were conducted with â€ẫ €ẫ €˜In-labeledBrE-3 using an MXDTPA chelate (18) . Very successful imaging was obtained, where 86% of all known lesions were localized (18) . In radioimmunotherapy trials using @Â°Y-MX DTPA-labeled BrE-3, with doses below maximal tolerable doses, there was a partial response in two of six patients (19) , while suprale thal doses with bone marrow support showed a partial response in 50% of the patients (20) . The most straight forward interpretation of these results is that the cell-associated mucin is less glycosylated than that which is released into the circulation. Thus, BrE-3, which iden tifies a less glycosylated tumor-associated mucin, is better for therapy, while Mc5, which identifies the more glycosylated mucin that is released into the circulation, is better as a diagnostic reagent for construction of serum assays (21) .
Epitopes on the Adhesion Molecule, BA46, and Radioimmuno therapy. A novel antigen that we have identified in the HMFG membrane and that is expressed in breast carcinoma cells is a Mr 46,000 glycoprotein (BA46), recognized by four MAbs: Mc3, Mc8, Mc15, and Mc16 (1). The BA46 cDNA (to be published elsewhere) has a single open reading frame that codes for a polypeptide consist ing of an NH2-terminal signal peptide sequence, followed by an EGF-like domain into which a cell adhesion sequence (RGD) is inserted, and a COOH-terminal domain with homology to the phos pholipid binding Cl/C2 domain of coagulation factors V and Vifi (5) .
Although the derived amino acid sequence suggests a soluble glycoprotein, BA46 is a major component of the HMFG membrane (22) , separates in the membrane fraction of breast carcinoma cells (23) , and is expressed on the surface of mammalian cells transfected with the complete BA46 cDNA.4 Also, it separates in the detergent phase, using Triton X-1 14 fraction procedures on breast cell lines (5). If HMFG is fractionated with Triton X-ll4 with centrifugation at 10,000 X g, BA46 is obtained in the detergent phase (90% purity), while integral membrane proteins with transmembrane domains (e.g., breast mucin and butryophilin) are found in the pellet. The COOH terminal Cl/C2-like domain is possibly involved in its membrane association. Other proteins have also been found to contain Factor Also, it appears that the membrane-association site is proximal to the Mcl6 epitope toward the COOH-terminal. Furthermore, a portion of the BA46 antigen released by the transfected cells is particulate, possibly associated with membrane fragments or micelles, since at least 50% of the released BA46 can be pelleted at 10,000 X g. These results suggest that BA46 antigen is oriented on the cell surface with attachment at the C2 domain and the EGF-like ROD domain exposed on the surface. The greater radioimmunotherapy effectiveness of Mc3 may be related to the positioning of its epitope on the membrane and/or its binding to a potential function domain of the adhesion molecule. The Mc8 epitope may be less accessible due to its proximity to the membrane attachment site.
These results demonstrate that with two different breast epithe hal antigens, breast mucin and BA46 antigen, different epitopes on the same molecule can have considerable differences in their effectiveness as targets for radioimmunotherapy.
In the case of the breast mucin, these differences are probably due to the role of oligosaccharides in the epitopes resulting from alterations in gly cosylation that occur in breast carcinoma cells. In the case of the BA46 glycoprotein, it seems to be due to binding of the MAbs to different functional domains and the orientation of the molecule on the cell surface. The two MAbs that showed the most favorable biodistributions and effectiveness in radioimmunotherapy, BrE-3 for breast mucin and Mc3 for BA46, have both been humanized (31â€"33),and these humanized forms show identical affinities and biodistributions in an experimental mouse model (34) compared to their mouse counterparts. These detailed epitope structural studies clearly show that it is possible to develop MAbs against normal breast differentiation antigens that have appropriate breast tumor specificity for radioimmunotherapy. fat globules of mice, guinea pigs, and cattle (27, 28) , that also appear to lack any transmembrane domain. The mechanism of membrane association for BA46 may involve covalent linkage to phospholipids or fatty acids. The C1/C2 domain of coagulation factors V and Vifi appears to be involved in phospholipid binding, a necessary interac tion involved in coagulation (29) .
The cell adhesion sequence ROD (30) â€˜@â€˜I-and @Â°Y-labeled Mc3 were found to inhibit growth of the transplanted tumors. Moreover, with the latter radioimmunoconjugate, 6 of 7 of the mice were cured of their tumors (4) . To investigate the molecular basis for the different radioimmuno therapy effectiveness of these two MAbs against the BA46 antigen, additional studies were undertaken on their epitopes. Epitope mapping (6), using consecutive overlapping hexamer peptides encompassing the 53 amino acids of the COOH-terminal end (all within the C2-like domain), identified the epitopes of Mc8 and Mcl6 as adjacent se quences DPRTG and SSKIF, respectively (Fig. 4) . MAb Mc3 did not bind to any of these peptides. However, Mc3 bound to recombinant polypeptides produced in transfected E. coli, encompassing the entire mature BA46 amino acid sequence, as well as only the EGF-like RGD domain. Thus, all three MAbs bound to the polypeptide moiety of this glycoprotein: Mc3 to the EGF-likefRGD domain and Mc8 and Mcl6 to adjacent linear amino acid sequences in the C2 domain (Fig. 4) . The epitope of Mc3 did not appear to be in the cell adhesion sequence (ROD), since it would not inhibit recombinant BA46-promoted cell attachment.
The orientation of the BA46 antigen in the membrane was studied using indirect immunofluorescence. 
